Sugi Predict

Sugi Predict / Compounds / SCHEMBL5741708

SCHEMBL5741708

SCHEMBL5741708

CC(C)CN1CCN(c2ccc(N)cc2)CC1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 7/20 0.66
▸ GFER P55789 5/20 0.66
▸ KDM4E B2RXH2 4/20 0.66
▸ GAA P10253 4/20 0.66
▸ SMN1; SMN2 Q16637 3/20 0.66
▸ RAD52 P43351 2/20 0.66
▸ ALDH1A1 P00352 5/20 0.56
▸ KMT2A Q03164 4/20 0.56
▸ ADRA2C P18825 2/20 0.56
▸ PTK2B Q14289 1/20 0.56
▸ ESR2 Q92731 1/20 0.56
▸ LMNA P02545 3/20 0.52
▸ HTT P42858 2/20 0.52
▸ MAPK1 P28482 1/20 0.52
▸ TDP1 Q9NUW8 1/20 0.52
▸ L3MBTL1 Q9Y468 3/20 0.50
▸ CASP6 P55212 1/20 0.49
▸ MEN1 O00255 3/20 0.48
▸ NPC1 O15118 1/20 0.48
▸ USP2 O75604 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL519214 0.86 MAPT (0.62) MAPTGFERKDM4EGAASMN1; SMN2
SCHEMBL520715 0.86 MAPT (0.62) MAPTGFERKDM4EGAASMN1; SMN2
SCHEMBL519213 0.86 MAPT (0.62) MAPTGFERKDM4EGAASMN1; SMN2
SCHEMBL23866004 0.86 MAPT (0.54) MAPTGFERKDM4EGAASMN1; SMN2
SCHEMBL1047579 0.83 MAPT (0.62) MAPTGFERKDM4EGAASMN1; SMN2
SCHEMBL12535863 0.82 IGF1R (0.56) MAPTGFERKDM4EGAAALDH1A1
SCHEMBL6245192 0.82 IGF1R (0.56) MAPTGFERKDM4EGAASMN1; SMN2
SCHEMBL2767049 0.82 KDM4E (0.61) MAPTGFERKDM4EGAASMN1; SMN2
SCHEMBL17450396 0.82 MAPT (0.61) MAPTGFERKDM4EGAASMN1; SMN2
SCHEMBL1100438 0.81 ALDH1A1 (0.72) MAPTGFERKDM4EALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1383753-A1 PIPERAZINE-BENZAMIDE DERIVATIVES USEFUL AS APOB-100 AND/OR MTP INHIBITOR GLAXO GROUP LIMITED (GB) 2004-01-28 — — EP claimed
WO-2003047575-A1 THERAPEUTIC BENZAMIDE DERIVATIVES GLAXO GROUP LIMITED (GB) 2003-06-12 — — WO claimed
WO-2003048121-A1 THERAPEUTIC BENZAMIDE DERIVATIVES GLAXO GROUP LIMITED (GB) 2003-06-12 — — WO claimed
WO-2002083658-A1 PIPERAZINE-BENZAMIDE DERIVATIVES USEFUL AS APOB-100 AND/OR MTP INHIBITOR GLAXO GROUP LIMITED (GB) 2002-10-24 — — WO claimed
US-10752624-B2 Kinase inhibitors ORIGENIS GMBH (DE) 2020-08-25 — — US disclosed
US-20180305356-A1 NOVEL KINASE INHIBITORS ORIGENIS GMBH (DE) 2018-10-25 — — US disclosed
US-10000482-B2 Kinase inhibitors ORIGENIS GMBH (DE) 2018-06-19 — — US disclosed
US-9637491-B2 Pyrazolo[4,3-D]pyrimidines as kinase inhibitors ORIGENIS GMBH (DE) 2017-05-02 — — US disclosed
US-9499535-B2 Kinase inhibitors ORIGENIS GMBH (DE) 2016-11-22 — — US disclosed
EP-2699572-B1 HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2016-08-10 — — EP disclosed
EP-2699579-B1 PYRAZOLO[4,3-D]PYRIMIDINES USEFUL AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-10-07 — — EP disclosed
US-20150266882-A1 PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-09-24 — — US disclosed
US-20040082595-A1 Intermediates useful in the preparation of diaminothiazoles DING QINGJIE (US) 2004-04-29 — — US disclosed
EP-1383753-A1 PIPERAZINE-BENZAMIDE DERIVATIVES USEFUL AS APOB-100 AND/OR MTP INHIBITOR GLAXO GROUP LIMITED (GB) 2004-01-28 — — EP disclosed
EP-1358169-A2 DIAMINOTHIAZOLES AND THEIR USE AS INHIBITORS OF CYCLIN-DEPENDENT KINASE F. HOFFMANN-LA ROCHE AG (CH) 2003-11-05 — — EP disclosed
WO-2003047575-A1 THERAPEUTIC BENZAMIDE DERIVATIVES GLAXO GROUP LIMITED (GB) 2003-06-12 — — WO disclosed
WO-2003048121-A1 THERAPEUTIC BENZAMIDE DERIVATIVES GLAXO GROUP LIMITED (GB) 2003-06-12 — — WO disclosed
WO-2002083658-A1 PIPERAZINE-BENZAMIDE DERIVATIVES USEFUL AS APOB-100 AND/OR MTP INHIBITOR GLAXO GROUP LIMITED (GB) 2002-10-24 — — WO disclosed
US-20020151554-A1 Diaminothiazoles having antiproliferative activity CHEN LI (US) 2002-10-17 — — US disclosed
WO-2002057261-A2 DIAMINOTHIAZOLES AND THEIR USE AS INHIBITORS OF CYCLIN-DEPENDENT KINASE F. HOFFMANN-LA ROCHE AG (CH) 2002-07-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150266882-A1 PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS LRRK2, MYLK2, MYLK MAPT 501/4885GFER 4102/4885KDM4E 1409/4885
US-20180305356-A1 NOVEL KINASE INHIBITORS LRRK2, MYLK2, MYLK MAPT 470/4885GFER 3828/4885KDM4E 1662/4885
US-20020151554-A1 Diaminothiazoles having antiproliferative activity CDK4, CDK2, CDKL4 MAPT 3064/4885GFER 4289/4885KDM4E 973/4885
US-20040082595-A1 Intermediates useful in the preparation of diaminothiazoles CDK4, CDK2, CDKL4 MAPT 2939/4885GFER 3986/4885KDM4E 1021/4885
US-10000482-B2 Kinase inhibitors LRRK2, MYLK2, MYLK MAPT 438/4885GFER 3792/4885KDM4E 1645/4885
US-10752624-B2 Kinase inhibitors LRRK2, MYLK2, MYLK MAPT 438/4885GFER 3792/4885KDM4E 1645/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.